PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice

Biochemical and Biophysical Research Communications

Volumn 473, Issue 4, 2016, Pages 1039-1044

  Toba, Junya ^a   Nikkuni, Miyu ^a   Ishizeki, Masato ^a   Yoshii, Aya ^a   Watamura, Naoto ^a   Inoue, Takafumi ^a   Ohshima, Toshio ^a  

^a WASEDA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cerebellum; CRMP; Mouse; Protein phosphorylation

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; PIOGLITAZONE; PROTEIN P35; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; CDK5R1 PROTEIN, MOUSE; CRMP2 PROTEIN, RAT; NERVE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOTRANSFERASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBELLUM; CONTROLLED STUDY; LONG TERM DEPRESSION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CEREBELLAR DISEASES; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBELLAR DISEASES; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; PHOSPHOTRANSFERASES; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84963612238     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.04.012     Document Type: Article

References (31)

1. D.J. Selkoe Translating cell biology into therapeutic advances in Alzheimer's disease Nature 399 1999 23 31
2. T. Arendt Synaptic degeneration in Alzheimer's disease Acta Neuropathol. 118 2009 167 179
3. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problem on the road to therapeutics Science 297 2002 353 356
4. K. Blennow, N. Boqdanovic, I. Alafuzoff, and et al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele J. Neural Transm. 103 1996 603 618
5. S.T. Ferreira, and W.L. Klein The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease Neurobiol. Learn. Mem. 96 2011 529 543
6. D.M. Walsh, and et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo Nature 426 2002 535 539
7. Uchida, and et al. Semaphorin3A signaling is mediated via sequential Cdk5 and GSK3β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease Genes Cells 10 2005 165 179
8. N. Yamashita, and et al. Phosphorylation of CRMP2 (collapsin response mediator protein 2) is involved in proper dendritic field organization J. Neurosci. 32 2012 1360 1365
9. Y. Gu, N. Hamajima, and Y. Ihara Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522 Biochemistry 39 2000 4267 4275
10. A.R. Cole, and et al. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression J. Neurochem. 103 2007 1132 1144
11. R.K. Semple, V. Chatterjee, and S. O'Rahilly PPARγ and human metabolic disease J. Clin. Invest. 116 2006 581 589
12. M. Heneka, and G. Landreth PPARs in the brain Biochem. Biophys. Acta 1771 2007 1031 1045
13. M. Kobayashi, M. Iwanishi, K. Egawa, and Y. Shigeta Pioglitazone increases insulin sensitivity by activating insulin receptor kinase Diabetes 41 1992 476 483
14. M. Heneka, M. Sastre, L. Dumitrescu-Ozimek, and et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice Brain 128 2005 1442 1453
15. S. Mandrekar-Colucci, J.C. Karlo, and G.E. Landreth Mechanisms underlying the rapid peroxisome proliferator- activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease J. Neurosci. 32 2013 10117 10128
16. Y. Kuwabara, M. Ishizeki, N. Watamura, and et al. Impairments of long-term depression induction and motor coordination precede Aβ accumulation in the cerebellum of APPswe/PS1dE9 double transgenic mice J. Neurochem. 130 2014 432 443
17. J.L. Jankowsky, and et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies Biomol. Eng. 17 2001 157 165
18. Q.S. Chen, B.L. Kagan, Y. Hirakura, and C.W. Xie Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides J. Neurosci. Res. 60 2000 65 72
19. T. Alkam, A. Nitta, H. Mizoguchi, and et al. The extensive nitration of neurofilament light chain in hippocampus is associated with the cognitive impairment induced by amyloid beta in mice J. Pharmacol. Exp. Ther. 327 2008 137 147
20. J. Goto, T. Inoue, A. Kuruma, and K. Mikoshiba Short-term potentiation at the parallel fiber-Purkinje cell synapse Neurosci. Res. 55 2006 28 33
21. X. He, M. Ishizeki, N. Mita, and et al. Cdk5/p35 is required for motor coordination and cerebellar plasticity J. Neurochem. 131 2014 53 64
22. V. Shukla, S. Skuntz, and H.C. Pant Deregulated Cdk5 activity is involved in inducing Alzheimer's disease Arch. Med. Res. 43 2012 655 662
23. G.N. Patrick, and et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration Nature 402 1999 615 622
24. P.F. Chapman, and et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice Nat. Neurosci. 2 1999 271 276
25. 25-35 induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2 Neurosci. Res. 77 2013 180 185
26. T. Vaisid, N.S. Kosower, A. Katzav, and et al. Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse of Alzheimer's disease Neurochem. Int. 51 2007 391 397
27. K. Sato, and et al. Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25 J. Neurochem. 117 2011 504 515
28. G.N. Patrick, P. Zhou, Y.T. Kwon, and et al. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway J. Biol. Chem. 273 1998 24057 24064
29. B.P. Tseng, K.N. Green, J.L. Chan, and et al. Aβ inhibits the proteasome and enhances amyloid and tau accumulation Neurobiol. Aging. 29 2008 1607 1618
30. Cho D.H. et al. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons. J. Neurochem. 126, 685-695 (126).
31. J. Chen, S. Li, W. Sun, and J. Li Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity PlosOne 10 2015 1 12